top of page


Aspirar's Toxicology Lab offers several protocols to meet the needs of specific markets. These have been designed by industry experts to encompass the entire drug testing life cycle - from how specimens are collected to the types of tests conducted to the formatting of reports. We take pride in working with each physician to customize our protocols to better address your unique requirements.


We provide EIA screening (semi-quantitative method) and/or LCMSMS technology (confirmatory method) , Aspirar Medical Lab provides practitioners with a definitive analysis of a wide array of substances in an easy-to-read report format. We perform testing based on physician directives. In addition, we encourage practices to carefully evaluate each test option in conjunction with the patient’s history and examination to make certain that all testing is appropriate and medically necessary. 


Aspirar Medical Lab is committed to our role in educating physicians on the requirement by the OIG/HHS that all testing ordered must be deemed medically necessary. As part of our compliance plan, we offer full disclosure of the CPT codes we will bill with, along with the corresponding Medicare Fees so that providers may consider those facts as they make their selections.

Senior Doctor



Our CLIA certified laboratory provides drug testing services to medical practices nationwide. Below is an overview of some of the most common panel we offer:

Screening & Comprehensive Drug Monitoring – Urine Includes:


Confirmations (THC, Cocaine, PCP, MDMA, Heroin, Amphetamine, Methamphetamine, Alprazolam, Diazepam, Triazolam, Lorazepam, Temazepam, Buprenorphine, Carisoprodol, Fentanyl, Meperidine, Methadone, Morphine, Codeine, Hydrocodone, Hydromorphone, Oxycodone, Oxymorphone, Tramadol, Tapentadol, Alcohol in EIA orders for a comprehensive drug monitoring – urine include validity testing (creatinine, pH, specific gravity, oxidant)

1. Specimen Validity Testing 

Once a urine specimen is received in one of our labs, it is scanned into the system and receives a lab accession number for the most reliable identification and tracking. Afterwards, the sample undergoes validity testing using pH values, specific gravity and creatinine to ensure it is a human sample and that it has not been diluted or adulterated.


2. Initial Screening 

An initial Enzyme Immunoassay (EIA) test screens for the presence of opiates, benzodiazepines, illicits and other prescribed or non-prescribed medications.


3. Confirmation Testing 

If the EIA test result is positive, the sample undergoes confirmation testing through liquid chromatography: a tandem mass spectrometry (LC/MS/MS) is used when optimal specificity and sensitivity are required to determine the absence or presence of your patients’ prescribed medications as well as the presence of non-prescribed medications or illicits. The methodology to obtain confirmation depends on the type of drug being tested.


4. Results Report 

Results are delivered in a comprehensive report, which includes your patient’s normalized value and compares it to a reference database.

Why Choose Aspirar for all of Your Toxicology Testing Needs?

  • CLIA & COLA Accredited Laboratory

  • Semi-Quantitative Screening

  • Full Confirmation Panels

  • Multiple Testing Options with ability to test up to 84 controlled substances

  • Validity Testing (creatinine, pH, specific gravity, oxidant)

  • Rigorously Validated Protocols

  • Validated Sample Type: Urine

  • Supplies & Equipment Provided

  • Rapid Result Turnaround with Ability to Handle High Sample Volume

  • Excellent Customer Service & Knowledgeable Staff to Assist with any Questions or Needs

  • EMR Integration

  • Nationwide Coverage

Aspirar Logo
bottom of page